Invokana maintains reduction in weight loss, BP at 1 year

Long-term canagliflozin use was associated with reduced body weight and a dose-dependent reduction in BP compared with placebo among patients with type 2 diabetes, according to findings presented at the American Heart Association Scientific Sessions. To https://www.healio.com/cardiology/diabetes/news/online/%7B59375aed-a727-4c8a-ab54-b7b6ef90777e%7D/invokana-maintains-reduction-in-weight-loss-bp-at-1-year